![Aldeyra Therapeutics, Inc. logo](/logos/ALDX.webp)
Aldeyra Therapeutics, Inc.
NASDAQ:ALDX
Overview | Financials
Company Name | Aldeyra Therapeutics, Inc. |
Symbol | ALDX |
Currency | USD |
Price | 6.13 |
Market Cap | 364,254,408 |
Dividend Yield | 0% |
52-week-range | 1.42 - 7.42 |
Industry | Biotechnology |
Sector | Healthcare |
CEO | Dr. Todd C. Brady M.D., Ph.D. |
Website | https://www.aldeyra.com |
An error occurred while fetching data.
About Aldeyra Therapeutics, Inc.
Aldeyra Therapeutics, Inc., a biotechnology company, develops and commercializes medicines for immune-mediated ocular and systemic diseases. The company's lead product candidate is reproxalap, a reactive aldehyde species (RASP)modulator, which is in Phase III clinical trial for the treatment of dry eye diseases and allergic conjunctivitis. It also develops ADX-629, a
Related Stocks
Financials
Numbers are in millions USD
Numbers are in millions USD